Celcuity Reports Gedatolisib-Darolutamide mCRPC Data

Updated Phase 1b/2 data showed median rPFS of 15.7 months and rPFS6 of 82.2% after prior abiraterone, versus 9.1 months and 62.5% after prior enzalutamide. Phase 2 is expected to begin in H1 2027.